Study Information
Status: Active, Recruiting
Study Details
View study details on clinicaltrials.gov.
Locations
Greater Sacramento Valley
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
A Phase 2 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of SPR001 (Tildacerfont) in Children Aged 2 to 17 Years With Congenital Adrenal Hyperplasia
This is a study to evaluate the safety and efficacy of tildacerfont in participants with Congenital Adrenal Hyperplasia (CAH). Treatment will consist of 4 or 12 weeks of continuous dosing followed by safety follow up.
Location: SIMR (Sacramento/Valley Area)
Please contact: SIMR@sutterhealth.org about Spruce 205